vs
爵士制药（JAZZ）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是爵士制药的1.2倍（$1.5B vs $1.2B），爵士制药净利率更高（17.0% vs -3.1%，领先20.1%），爵士制药同比增速更快（10.1% vs -11.9%），爵士制药自由现金流更多（$345.8M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs 15.2%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
JAZZ vs RXO — 直观对比
营收规模更大
RXO
是对方的1.2倍
$1.2B
营收增速更快
JAZZ
高出22.0%
-11.9%
净利率更高
JAZZ
高出20.1%
-3.1%
自由现金流更多
JAZZ
多$354.8M
$-9.0M
两年增速更快
RXO
近两年复合增速
15.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.5B |
| 净利润 | $203.5M | $-46.0M |
| 毛利率 | — | — |
| 营业利润率 | 21.2% | -2.9% |
| 净利率 | 17.0% | -3.1% |
| 营收同比 | 10.1% | -11.9% |
| 净利润同比 | 6.5% | -84.0% |
| 每股收益（稀释后） | $3.34 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZRXO
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $897.8M | $1.4B | ||
| Q4 24 | $1.1B | $1.7B | ||
| Q3 24 | $1.1B | $1.0B | ||
| Q2 24 | $1.0B | $930.0M | ||
| Q1 24 | $902.0M | $913.0M |
净利润JAZZRXO
| Q4 25 | $203.5M | $-46.0M | ||
| Q3 25 | $251.4M | $-14.0M | ||
| Q2 25 | $-718.5M | $-9.0M | ||
| Q1 25 | $-92.5M | $-31.0M | ||
| Q4 24 | $191.1M | $-25.0M | ||
| Q3 24 | $215.1M | $-243.0M | ||
| Q2 24 | $168.6M | $-7.0M | ||
| Q1 24 | $-14.6M | $-15.0M |
营业利润率JAZZRXO
| Q4 25 | 21.2% | -2.9% | ||
| Q3 25 | 5.1% | -0.5% | ||
| Q2 25 | -65.6% | — | ||
| Q1 25 | -6.2% | -2.1% | ||
| Q4 24 | 17.5% | -1.4% | ||
| Q3 24 | 24.7% | -1.9% | ||
| Q2 24 | 19.5% | — | ||
| Q1 24 | 7.3% | -1.3% |
净利率JAZZRXO
| Q4 25 | 17.0% | -3.1% | ||
| Q3 25 | 22.3% | -1.0% | ||
| Q2 25 | -68.7% | -0.6% | ||
| Q1 25 | -10.3% | -2.2% | ||
| Q4 24 | 17.6% | -1.5% | ||
| Q3 24 | 20.4% | -23.4% | ||
| Q2 24 | 16.5% | -0.8% | ||
| Q1 24 | -1.6% | -1.6% |
每股收益（稀释后）JAZZRXO
| Q4 25 | $3.34 | $-0.28 | ||
| Q3 25 | $4.08 | $-0.08 | ||
| Q2 25 | $-11.74 | $-0.05 | ||
| Q1 25 | $-1.52 | $-0.18 | ||
| Q4 24 | $2.97 | $-0.17 | ||
| Q3 24 | $3.42 | $-1.81 | ||
| Q2 24 | $2.49 | $-0.06 | ||
| Q1 24 | $-0.23 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $17.0M |
| 总债务越低越好 | $5.4B | $387.0M |
| 股东权益账面价值 | $4.3B | $1.5B |
| 总资产 | $11.7B | $3.3B |
| 负债/权益比越低杠杆越低 | 1.24× | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资JAZZRXO
| Q4 25 | $1.4B | $17.0M | ||
| Q3 25 | $1.3B | $25.0M | ||
| Q2 25 | $1.2B | $18.0M | ||
| Q1 25 | $1.9B | $16.0M | ||
| Q4 24 | $2.4B | $35.0M | ||
| Q3 24 | $2.2B | $55.0M | ||
| Q2 24 | $1.4B | $7.0M | ||
| Q1 24 | $1.4B | $7.0M |
总债务JAZZRXO
| Q4 25 | $5.4B | $387.0M | ||
| Q3 25 | $5.4B | $387.0M | ||
| Q2 25 | $5.4B | $387.0M | ||
| Q1 25 | $5.4B | $387.0M | ||
| Q4 24 | $6.1B | $351.0M | ||
| Q3 24 | $6.1B | $352.0M | ||
| Q2 24 | $5.7B | $370.0M | ||
| Q1 24 | $5.7B | $351.0M |
股东权益JAZZRXO
| Q4 25 | $4.3B | $1.5B | ||
| Q3 25 | $4.0B | $1.6B | ||
| Q2 25 | $3.7B | $1.6B | ||
| Q1 25 | $4.2B | $1.6B | ||
| Q4 24 | $4.1B | $1.6B | ||
| Q3 24 | $4.2B | $1.7B | ||
| Q2 24 | $3.8B | $579.0M | ||
| Q1 24 | $3.7B | $582.0M |
总资产JAZZRXO
| Q4 25 | $11.7B | $3.3B | ||
| Q3 25 | $11.4B | $3.2B | ||
| Q2 25 | $10.9B | $3.2B | ||
| Q1 25 | $11.5B | $3.3B | ||
| Q4 24 | $12.0B | $3.4B | ||
| Q3 24 | $12.3B | $3.4B | ||
| Q2 24 | $11.4B | $1.8B | ||
| Q1 24 | $11.3B | $1.8B |
负债/权益比JAZZRXO
| Q4 25 | 1.24× | 0.25× | ||
| Q3 25 | 1.35× | 0.24× | ||
| Q2 25 | 1.45× | 0.24× | ||
| Q1 25 | 1.29× | 0.24× | ||
| Q4 24 | 1.49× | 0.22× | ||
| Q3 24 | 1.47× | 0.21× | ||
| Q2 24 | 1.52× | 0.64× | ||
| Q1 24 | 1.54× | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $345.8M | $-9.0M |
| 自由现金流率自由现金流/营收 | 28.9% | -0.6% |
| 资本支出强度资本支出/营收 | 1.4% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.78× | — |
| 过去12个月自由现金流最近4个季度 | $1.3B | $-8.0M |
8季度趋势，按日历期对齐
经营现金流JAZZRXO
| Q4 25 | $362.5M | $7.0M | ||
| Q3 25 | $474.6M | $23.0M | ||
| Q2 25 | $88.9M | $23.0M | ||
| Q1 25 | $429.8M | $-2.0M | ||
| Q4 24 | $398.6M | $-7.0M | ||
| Q3 24 | $398.7M | $-7.0M | ||
| Q2 24 | $331.4M | $-5.0M | ||
| Q1 24 | $267.2M | $7.0M |
自由现金流JAZZRXO
| Q4 25 | $345.8M | $-9.0M | ||
| Q3 25 | $459.4M | $9.0M | ||
| Q2 25 | $75.9M | $9.0M | ||
| Q1 25 | $415.9M | $-17.0M | ||
| Q4 24 | $385.3M | $-19.0M | ||
| Q3 24 | $388.0M | $-18.0M | ||
| Q2 24 | $324.3M | $-16.0M | ||
| Q1 24 | $260.3M | $-4.0M |
自由现金流率JAZZRXO
| Q4 25 | 28.9% | -0.6% | ||
| Q3 25 | 40.8% | 0.6% | ||
| Q2 25 | 7.3% | 0.6% | ||
| Q1 25 | 46.3% | -1.2% | ||
| Q4 24 | 35.4% | -1.1% | ||
| Q3 24 | 36.8% | -1.7% | ||
| Q2 24 | 31.7% | -1.7% | ||
| Q1 24 | 28.9% | -0.4% |
资本支出强度JAZZRXO
| Q4 25 | 1.4% | 1.1% | ||
| Q3 25 | 1.3% | 1.0% | ||
| Q2 25 | 1.2% | 1.0% | ||
| Q1 25 | 1.5% | 1.0% | ||
| Q4 24 | 1.2% | 0.7% | ||
| Q3 24 | 1.0% | 1.1% | ||
| Q2 24 | 0.7% | 1.2% | ||
| Q1 24 | 0.8% | 1.2% |
现金转化率JAZZRXO
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.97× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
